OMX Nordic 40
2.328,27
PKT
-25,23
PKT
-1,07
%
Werbung
Analysen zu OMX Nordic 40-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 04.06.24 | AstraZeneca Sell | UBS AG | |
| 03.06.24 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 30.05.24 | Novo Nordisk Buy | Goldman Sachs Group Inc. | |
| 30.05.24 | AstraZeneca Buy | Goldman Sachs Group Inc. | |
| 28.05.24 | Novo Nordisk Buy | Deutsche Bank AG | |
| 28.05.24 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 28.05.24 | Hennes Mauritz (H M, H&M) Underweight | JP Morgan Chase & Co. | |
| 24.05.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 23.05.24 | ABB (Asea Brown Boveri) Sector Perform | RBC Capital Markets | |
| 23.05.24 | Volvo (B) Sector Perform | RBC Capital Markets | |
| 22.05.24 | Hennes Mauritz (H M, H&M) Sell | Goldman Sachs Group Inc. | |
| 22.05.24 | AstraZeneca Hold | Deutsche Bank AG | |
| 22.05.24 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 21.05.24 | AstraZeneca Sell | UBS AG | |
| 20.05.24 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 17.05.24 | Hennes Mauritz (H M, H&M) Outperform | RBC Capital Markets | |
| 16.05.24 | Hennes Mauritz (H M, H&M) Underweight | JP Morgan Chase & Co. | |
| 15.05.24 | Volvo (B) Buy | Goldman Sachs Group Inc. | |
| 15.05.24 | AstraZeneca Sell | UBS AG | |
| 15.05.24 | Novo Nordisk Neutral | UBS AG | |
| 14.05.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 14.05.24 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 14.05.24 | Novo Nordisk Neutral | UBS AG | |
| 13.05.24 | ABB (Asea Brown Boveri) Hold | Jefferies & Company Inc. | |
| 13.05.24 | Volvo (B) Sell | UBS AG | |
| 08.05.24 | Novo Nordisk Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 08.05.24 | AstraZeneca Hold | Jefferies & Company Inc. | |
| 07.05.24 | Novo Nordisk Overweight | Barclays Capital | |
| 07.05.24 | AstraZeneca Buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 06.05.24 | Novo Nordisk Neutral | UBS AG | |
| 03.05.24 | Novo Nordisk Halten | DZ BANK | |
| 03.05.24 | Novo Nordisk Buy | Deutsche Bank AG | |
| 03.05.24 | A.P. Moeller - Maersk A-S (B) Neutral | Goldman Sachs Group Inc. | |
| 03.05.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 02.05.24 | ABB (Asea Brown Boveri) Buy | Goldman Sachs Group Inc. | |
| 02.05.24 | Novo Nordisk Overweight | Barclays Capital | |
| 02.05.24 | A.P. Moeller - Maersk A-S (B) Neutral | Goldman Sachs Group Inc. | |
| 02.05.24 | Novo Nordisk Neutral | UBS AG | |
| 02.05.24 | A.P. Moeller - Maersk A-S (B) Buy | UBS AG | |
| 02.05.24 | A.P. Moeller - Maersk A-S (B) Underperform | Bernstein Research |